NCT03183557 is a Phase 2 clinical trial of "Zoledronic acid", "Reclast®" in Osteoporosis, sponsored by Shinshu University.

Who is sponsoring NCT03183557?

NCT03183557 is sponsored by Shinshu University.

What drugs are being tested in NCT03183557?

Interventions in NCT03183557: "Zoledronic acid", "Reclast®", "Zoledronic acid", "Reclast®" and "active vitamin D", "alfacalcidol®".

What condition does NCT03183557 study?

NCT03183557 studies Osteoporosis.

Is NCT03183557 still recruiting?

NCT03183557 is currently status unknown. Last updated 21 September 2021.

Last reviewed 2021-09-21 · How we verify

NCT03183557

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Zoledronic Acid in Osteoporosis

Status unknown Phase 2 Last updated 21 September 2021

What this trial tests

Phase 2 trial testing "Zoledronic acid", "Reclast®" in Osteoporosis in 100 participants. Status unknown.

Timeline

12 October 2017

Primary endpoint
8 December 2022

8 June 2025

Quick facts

Lead sponsor	Shinshu University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	100
Start date	12 October 2017
Primary completion	8 December 2022
Estimated completion	8 June 2025
Sites	1 location across Japan

Drugs / interventions tested

"Zoledronic acid", "Reclast®" — full drug profile →
"Zoledronic acid", "Reclast®" and "active vitamin D", "alfacalcidol®" — full drug profile →

Conditions studied

Osteoporosis — all drugs for Osteoporosis →

Sponsor

Shinshu University

Who can join

20 and older, any sex, with Osteoporosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There has been no comparative data between Zoledronic acid and Zoledronic acid combined with active vitamin D in primary and secondary osteoporosis.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Regulation of bone homeostasis: signaling pathways and therapeutic targets.
Wu Z, Li W, Jiang K, Lin Z, et al · · 2024 · cited 42× · PMID 39049966 · DOI 10.1002/mco2.657
Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis.
Uehara M, Nakamura Y, Suzuki T, Nakano M, et al · · 2021 · cited 5× · PMID 34830702 · DOI 10.3390/jcm10225420

Verify or expand the search:

Other recruiting trials for Osteoporosis

Currently open trials in the same condition.

NCT07027306 — The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fract · recruiting
NCT07367776 — Patient Education in Osteoporosis (RCT-PATOS) · NA · recruiting
NCT06731608 — OsteoPorotic fracTure preventION System (OPTIONS) Research Study · NA · recruiting
NCT07281586 — Step-down Therapy After Long-term Osteoporosis Treatment · Phase 4 · recruiting
NCT07083557 — Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiome · recruiting

Other Shinshu University trials

Trials by the same sponsor.

NCT05469659 — Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD) · Phase 2 · recruiting
NCT03784261 — Usefulness of Non TNF Usage in RA Patients · Phase 2 · unknown
NCT03755193 — Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosi · Phase 2 · recruiting
NCT03755466 — Examination of Efficacy and Safety of Baricitinib in RA Patients · Phase 2 · unknown
NCT03702140 — Examination How the Administration Period of Teriparatide Affects Bone Metabolism and Bone Mineral Density Prior to Deno · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03183557 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shinshu University
Last refreshed: 21 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03183557.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing